Pilot evaluation of the efficacy and safety of caninized anti-TNF-alpha monoclonal antibody therapy to treat refractory canine atopic dermatitis in dogs
Atopic dermatitis is a common chronic allergic skin disease of humans and dogs. Among the molecules known to be present in the skin of dogs with atopic dermatitis is the cytokine Tumor Necrosis Factor (TNF)-alpha, an upstream mediator that triggers a wide array of secondary inflammatory reactions. The goal of this study is to inject client-owned dogs with natural atopic dermatitis with a dog monoclonal antibody that blocks TNF-alpha, hoping to prevent inflammatory events leading to skin lesions and itch. Study participation is 6 weeks.
- Demonstrable IgE hypersensitivity to at least one allergen using either allergen-specific IgE serology or intradermal skin testing
- A lack of acceptable control of AD signs with standard of care treatment (steroids, cyclosporine) or unacceptable side-effects
- Nonseasonal moderate pruritic atopic dermatitis
- A moderate level of skin lesions associated with atopic dermatitis
- Deemed free of skin and ear infections at the time of enrollment
- Other specific selection parameters may apply. See contact below for more details.
The study will cover investigational drug cost and certain exams. Please see the contact below for more details.
NCSU Dermatology Service at 919-513-6543 or the Clinical Studies Core at firstname.lastname@example.org
Page last updated October 17, 2013